If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLSAI.L Regulatory News (LSAI)

  • There is currently no data for LSAI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results and Annual Financial Report

12 May 2009 11:17

RNS Number : 0924S
Longships PLC
12 May 2009
 



LONGSHIPS PLC ("Longships" or the "Company")

ANNUAL REPORT FOR THE PERIOD ENDED 31st DECEMBER 2008

Longships is pleased to announce its annual results for the year ending 31st December 2008.

The accounts are today being posted to the shareholders in accordance with Rule 20 of the AIM Rules and are available on the Company's website, http://production.inventis.com/longships/ .

Enquiries:

Longships Plc Tel: 020 7389 5017

Charles Cannon-Brookes, Investment Director

Grant Thornton UK LLP (Nominated Adviser) Tel: 020 7383 5100

Colin Aaronson

CHAIRMAN'S STATEMENT

FOR THE PERIOD ENDED 31ST DECEMBER 2008

Dear Shareholder,

I am pleased to present my first Chairman’s report covering the period from the Company’s incorporation to 31st December 2008. During the period under review, the Company reported a profit of £2,765 and as at 31st December 2008 had liquid cash balances of £3,355,556 (30th June 2008: £3,341,204). Various investment propositions were reviewed over the period and, although none as yet have met the Board’s investment criteria, the search continues for a suitable opportunity. I look forward to updating shareholders on progress in due course.
 
Craig Niven
Chairman
 
11th May 2009
 

 

INCOME STATEMENT 

FOR THE PERIOD ENDED 31st DECEMBER 2008

 

Notes

2008

£

NET TRADING INCOME

-

---------------

Share based payment charge

(21,588)

Other operating expenses

(78,999)

----------------

Total operating expenses

(100,587)

----------------

OPERATING LOSS

(100,587)

Finance income

109,729

----------------

PROFIT BEFORE TAXATION

9,142

Taxation

5

6,377

----------------

PROFIT FOR THE PERIOD

2,765

============

Earnings per share (pence) - basic and fully diluted

6

0.02p

=======

All of the activities of the Company are classed as continuing.

 

BALANCE SHEET AS AT 31st DECEMBER 2008

2008

Notes

£

CURRENT ASSETS

Trade and other receivables

7

9,083

Cash and cash equivalents

3,355,556

----------------

3,364,639

CURRENT LIABILITIES

Trade and other payables

8

(22,524)

----------------

NET CURRENT ASSETS

3,342,115

----------------

NET ASSETS

3,342,115

===========

EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY

Share capital

9

230,800

Share premium account

3,086,962

Share based payment reserve

21,588

Retained earnings

2,765

----------------

TOTAL EQUITY

3,342,115

=============

The financial statements were approved and authorised for issue by the directors on 11th May 2009 and were signed on their behalf by:

Craig Niven

Director

 

CASH FLOW STATEMENT 

FOR THE PERIOD ENDED 31st DECEMBER 2008

2008

 

Notes

£

Net cash outflow from operating activities

10

(71,935)

----------------

Cash flows from investing activities

Interest received

109,729

----------------

Cash flows from financing activities

Net proceeds from issue of share capital

3,317,762

------------------

Net increase in cash and cash equivalents

3,355,556

Cash and cash equivalents at beginning of period

-

------------------

Cash and cash equivalents at end of period

3,355,556

=============

STATEMENT OF CHANGES IN NET EQUITY 

FOR THE PERIOD ENDED 31st DECEMBER 2008

 

 
Share capital
Share premium
Share based payment reserve
Retained earnings
Total
 
£
£
£
£
£
 
 
 
 
 
 
At 20th December 2007
-
-
-
-
-
Shares issued for cash
230,800
3,173,200
-
-
3,404,000
Profit for period
-
-
-
2,765
2,765
Share issue costs
-
(86,238)
-
-
(86,238)
Share-based payments
-
-
21,588
-
21,588
 
________
_________
_________
__________
_________
At 31st December 2008
230,800
3,086,962
21,588
2,765
3,342,115
 
=======
========
========
=========
========

NOTES TO THE FINANCIAL STATEMENTS 

1.  GENERAL

The Company was incorporated on 20th December 2007 as a public limited company, incorporated and domiciled in England and Wales. These financial statements are the first to be prepared by the Company, and cover the period from incorporation to 31st December 2008. As this is the first accounting period of the Company, there are no comparative figures to be presented.

2.  ACCOUNTING POLICIES

Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRSs") as adopted by the European Union and as issued by the International Accounting Standards Board.

Trading income

Trading income is recognised to the extent that it is probable that economic benefit will flow to the Company and the trading income can be reliably measured.

Cash and cash equivalents

Cash and cash equivalents are defined as cash in hand, demand deposits and short-term, highly liquid investments which are readily convertible to known amounts of cash, subject to insignificant risk of changes in value, and have a maturity of less than 3 months from the date of acquisition.

For the purposes of the cash flow statement, cash and cash equivalents consist of cash in hand and bank deposits.

Taxation

The tax currently payable is based on the taxable profit for the period. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other periods and it further excludes items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Deferred taxation

Deferred income tax is provided for using the liability method on temporary timing differ­ences at the balance sheet date between tax basis of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax liabilities are recognised in full for all temporary differences. Deferred tax assets are recognised for all deductible temporary differ­ences carried forward of unused tax credits and unused tax losses to the extent that it is prob­able that taxable profit will be available against which the deductible temporary differences, and carry-forward of unused tax credits and unused losses can be utilised.

The carrying amount of deferred income tax assets is assessed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised. Unrecognised deferred income tax assets are reassessed at each balance sheet date and are recognised to the extent that is probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability settled, based on tax rates that have been enacted or substantively enacted at the balance sheet date.

Share-based payments

Certain Directors of the Company receive remuneration in the form of share-based payment transactions (equity-settled transactions).

The cost of equity-settled transactions is determined with reference to the fair value at the date on which they were granted. The fair value is determined by using the Black-Scholes option pricing model. 

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the service conditions are fulfilled, ending on the date on which the relevant employees become fully entitled to the award ("the vesting date"). The cumulative expense recognised for equity-settled transactions at each re­porting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The income statement charge or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period.

The dilutive effect of the outstanding options is reflected as additional dilution in the compu­tation of earnings per share.

Financial instruments

Financial assets and financial liabilities are recognised on the Company's balance sheet when the Company becomes a contractual party to the instrument.

Trade receivables

Trade receivables are recognised initially at their fair value which equates to their nominal value as reduced by appropriate provision for irrecoverable amounts and subsequently at amortised cost.

Trade payables

Trade payables are recognised initially at their fair value and subsequently at amortised cost.

Accounting judgements and key sources of estimation uncertainty

The preparation of financial statements in accordance with IFRSs requires management to make estimates and assumptions in certain circumstances that affect reported amounts. The most sensitive estimate affecting the financial statements is the area of share based payments. Actual outcomes may therefore differ from these estimates and assumptions.

 In determining the fair value of equity settled share based payments and the related charge to the income statement, the Company makes assumptions about future events and market conditions. In particular, judgment must be made as to the likely number of shares that will vest and the fair value of each award granted. The fair value is determined using a valuation model which is dependent on further estimates including the Company's future dividend policy, employee turnover, the timing of the exercise of options and the future volatility in the price of the Company's shares.  Such assumptions are based on publicly available information and reflect market expectations. Different assumptions from those used (which are disclosed in note 9) could materially affect the reported value of share based payments. The Company has recognised a corresponding increase in equity in accordance with IFRS 2: Share based payments by crediting "Share based payment reserve" (a component of equity) for the issue of shares in connection with the share options.

Standards and interpretations issued but not yet effective

The Company has not early adopted the following new and amended IAS, IFRS and IFRIC Interpretations issued. The relevant new and amended IAS, IFRS and IFRIC Interpretations will be adopted when they become effective.

IFRS 3 (Revised): Business combinations

IAS 1 (Revised): Presentation of financial statements

IAS 23: Borrowing costs

IFRIC 11/IFRS 2: Group and treasury share transactions

IFRIC 12: Service concession arrangements

IFRIC 13: Customer loyalty programs

IFRIC 14/IAS 19: The limit on a defined benefit asset, minimum funding requirements and their interaction

The directors anticipate that the adoption of these Standards and Interpretations in future periods will have no material impact on the financial statements of the Company in its current form. 

3. AUDITORS' REMUNERATION

2008

£

Services provided by the Company's auditors:

Fees payable to the company's auditors for the audit of the company's financial statements

10,000

Fees payable to the company's auditors for other services:

- Other services pursuant to legislation

4,113

- Corporate finance services

9,400

======

Corporate finance fees relate to the share placing on the AIM market in April 2008 and have been included in the share issue costs charged to the share premium account.

4. PARTICULARS OF EMPLOYEES

The average number of employees of the company in the period was:

2008

Number

Directors

3

======

£

The directors' aggregate emoluments in respect of qualifying services were:

Salary and short-term employment benefits

15,875

======

5. INCOME TAX EXPENSE

(a) Analysis of charge in the period

 
2008
 
£
Current tax:
 
 
 
UK corporation tax based on the results for the period at 20.75%
6,377
 
----------------
Total current tax
6,377
 
==========

(b) Factors affecting the tax charge for the period

The tax assessed for the period does not reflect an expense equivalent to the profit before tax multiplied by the standard rate of corporation tax of 20.75%.

2008

£

Profit before tax

9,142

=========

Profit before tax multiplied by the standard rate of corporation tax

1,897

Effects of:

Share options timing differences

4,480

------------

Current tax for the period

6,377

=========

6. EARNINGS PER SHARE

The calculation of earnings per share is based on the profit of £2,765 and on the number of shares in issue, being the weighted average number of shares in issue during the period of 16,641,695 ordinary £0.01 shares. There is no dilutive effect of share options on the basic earnings per share, as the option exercise prices are higher than the average market price in the period.

7. TRADE AND OTHER RECEIVABLES

2008

£

Prepayments

9,083

===============

The Directors consider that the carrying value of each class of receivable approximates its fair value.

8.  TRADE AND OTHER PAYABLES

2008

£

Trade payables

6,147

Current tax payable

6,377

Accrued expenses

10,000

--------------------

22,524

=============

9. SHARE CAPITAL

Share options

The Company granted and issued share options over ordinary shares in the Company as follows: 

Date granted

Parties

Exercise price

Number of shares

Final exercisable date

21/04/08

C Cannon-Brookes

20p

500,000

21/04/15

21/04/08

C Niven

20p

500,000

21/04/15

-------------------

1,000,000

Options outstanding at 20/12/07

-------------------

Options outstanding at 31/12/08

1,000,000

=============

The fair value of equity settle share options granted is estimated as at the date of grant using a Black-Scholes option pricing model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs into the model used for the period ended 31st December 2008:

2008 

Dividend yield on underlying shares

0%

Risk free rate

4%

Expected volatility

22.36%

Average time to expiry

1 year

Weighted average share price of options

20p

==========

 

The expected life of the options is based on an estimate and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not be the actual outcome.

Authorised share capital:

2008 

£ 

100,000,000 Ordinary shares of £0.01 each

1,000,000

==========================================

Allotted, called up and fully paid:

2008

£ 

23,080,002 Ordinary shares of £0.01 each 

230,800

===================================

On 20th December 2007, 2 subscriber shares were issued, on 28th February 2008, 8,080,000 shares were issued at 5 pence per share and on 21st April 2008, 15,000,000 shares were issued on floatation at 20 pence per share.

10. CASH FLOWS FROM OPERATING ACTIVITIES

2008

£

Profit before taxation

9,142

Adjustments for:

Interest income

(109,729)

Equity-settled share options

21,588

--------------------

(78,999)

Increase in receivables

(9,083)

Increase in payables

16,147

--------------------

Net cash from operating activities

(71,935)

=============

- END -

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR IIFVAEIIFLIA
Date   Source Headline
16th Feb 202412:30 pmRNSResult of General Meeting
6th Feb 202410:55 amRNSHolding(s) in Company
30th Jan 20248:00 amRNSSchedule One - Location Sciences Group Plc
30th Jan 20247:30 amRNSRestoration - Location Sciences Group PLC
30th Jan 20247:00 amRNSAcquisition and Publication of Admission Document
25th Jan 20247:00 amRNSLoan Facility and Holding in Company
20th Dec 20237:00 amRNSFurther update on proposed acquisition of Sorted
6th Oct 20237:00 amRNSUpdate on proposed acquisition of Sorted
14th Sep 20237:00 amRNSHalf-year Report
28th Jul 20231:22 pmRNSResult of AGM
25th Jul 20237:00 amRNSHolding(s) in Company
28th Jun 20237:30 amRNSSuspension - Location Sciences Group plc
28th Jun 20237:00 amRNSLoan Agreement, Proposed Acquisition & Suspension
26th Jun 20237:00 amRNSAnnual Financial Report
11th Apr 20234:56 pmRNSHolding(s) in Company
31st Mar 202311:50 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSHolding(s) in Company
22nd Mar 20233:47 pmRNSHolding(s) in Company
22nd Mar 20231:40 pmRNSHolding(s) in Company
22nd Mar 20239:05 amRNSSecond Price Monitoring Extn
22nd Mar 20239:00 amRNSPrice Monitoring Extension
15th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Sep 20227:00 amRNSHalf-year Report
30th Jun 202211:56 amRNSResult of AGM
6th Jun 20227:00 amRNSNotice of Annual General Meeting
1st Jun 20222:12 pmRNSDirector/PDMR Shareholding
1st Jun 20221:25 pmRNSDirector/PDMR Shareholding
1st Jun 20227:00 amRNSBoard and strategic update
5th Apr 202211:05 amRNSSecond Price Monitoring Extn
5th Apr 202211:00 amRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSAnnual Financial Report
1st Feb 20227:00 amRNSFurther re Sale of Insights dashboard
24th Jan 202211:05 amRNSSecond Price Monitoring Extn
24th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Oct 20218:05 amRNSSale of Insights dashboard
27th Sep 202112:09 pmRNSHalf-year Report
21st Jun 20211:27 pmRNSBusiness Review update and proposed Board changes
21st Jun 202111:28 amRNSHolding(s) in Company
18th Jun 202110:55 amRNSResult of AGM
11th Jun 202110:34 amRNSHolding(s) in Company
8th Jun 202111:54 amRNSHolding(s) in Company
1st Jun 20219:06 amRNSSecond Price Monitoring Extn
1st Jun 20219:00 amRNSPrice Monitoring Extension
28th May 20215:00 pmRNSTotal Voting Rights
28th May 20212:11 pmRNSHolding(s) in Company
27th May 20213:33 pmRNSTR-1 Notification of major holdings
25th May 20218:05 amRNSNotice of AGM
25th May 20218:01 amRNSBoard changes and appointment of Joint Broker
21st May 202111:14 amRNSGM Result, Issue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.